Table 1 Summary of findings and quality assessment for the qualitative analysis using grade profiler software
Randomised clinical studies to treat CIDP- summary of findings | ||||||
|---|---|---|---|---|---|---|
Outcomes | Intervention and comparison intervention | Illustrative comparative risks* (95% CI) | No of participants (studies) | Quality of the evidence (GRADE) | References | |
Assumed risk | Corresponding risk | |||||
With comparator | With intervention | |||||
Greater than 20% reduction in mean weekly dose of corticosteroids or IVIG | ||||||
Methotrexate/placebo (OR OR 1.38, 95% CI 0.5-3.87 ) | 438 per 1000 | 518 per 1000 (280 to 751) | 59 (1 study) | ⊕⊕⊕⊝ Moderate | [18] | |
Disease progression @ 32 weeks | ||||||
Interferon/placebo | 474 per 1000 | 343 per 1000 (146 to 620) | 54 (1 study) | ⊕⊕⊕⊝ Moderate | [20] | |
Responders | ||||||
Immunoadsorption/IVIG | 500 per 1000 | 800 per 1000 (231 to 982) | 13 (1 study) | ⊕⊝⊝⊝ Very low | [22] | |
IVIG/placebo | 222 per 1000 | 781 per 1000 (275 to 970) | 18 (1 study) | ⊕⊕⊕⊝ Moderate | [24] | |
IVIG/placebo | 231 per 1000 | 266 per 1000 (62 to 671) | 28 (1 study) | ⊕⊕⊝⊝ Low | [25] | |
IVIG/placebo | 207 per 1000 | 542 per 1000 (344 to 728) | 117 (1 study) | ⊕⊕⊕⊕ High | [27] | |
Rituximab/placebo | 77 per 1000 | 520 per 1000 (49 to 958) | 26 (1 study) | ⊕⊕⊕⊝ Moderate | [31] | |
Adverse treatment related effects | ||||||
Kiovig (10% liquid immunoglobulin)/Gammagard (5% freeze dried immunoglobulin standard) | 692 per 1000 | 714 per 1000 (321 to 929) | 27 (1 study) | ⊕⊕⊕⊝ Moderate | [29] | |
Remission at 12 months | ||||||
Pulsed high-dose dexamethasone/standard prednisolone treatment | 375 per 1000 | 417 per 1000 (165 to 723) | 40 (1 study) | ⊕⊕⊝⊝ Low | [32] | |